Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Evaluation of human primary intestinal monolayers for drug metabolizing capabilities.

Speer JE, Wang Y, Fallon JK, Smith PC, Allbritton NL.

J Biol Eng. 2019 Nov 4;13:82. doi: 10.1186/s13036-019-0212-1. eCollection 2019.

2.

A Sample-Sparing Multiplexed ADCP Assay.

Butler AL, Fallon JK, Alter G.

Front Immunol. 2019 Aug 13;10:1851. doi: 10.3389/fimmu.2019.01851. eCollection 2019.

3.

A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation.

Fischinger S, Fallon JK, Michell AR, Broge T, Suscovich TJ, Streeck H, Alter G.

J Immunol Methods. 2019 Oct;473:112630. doi: 10.1016/j.jim.2019.07.002. Epub 2019 Jul 10.

4.

Antiretroviral Drug Concentrations in Lymph Nodes: A Cross-Species Comparison of the Effect of Drug Transporter Expression, Viral Infection, and Sex in Humanized Mice, Nonhuman Primates, and Humans.

Burgunder E, Fallon JK, White N, Schauer AP, Sykes C, Remling-Mulder L, Kovarova M, Adamson L, Luciw P, Garcia JV, Akkina R, Smith PC, Kashuba ADM.

J Pharmacol Exp Ther. 2019 Sep;370(3):360-368. doi: 10.1124/jpet.119.259150. Epub 2019 Jun 24.

PMID:
31235531
5.

Targeted quantitative proteomic analysis of drug metabolizing enzymes and transporters by nano LC-MS/MS in the sandwich cultured human hepatocyte model.

Khatri R, Fallon JK, Rementer RJB, Kulick NT, Lee CR, Smith PC.

J Pharmacol Toxicol Methods. 2019 Jul - Aug;98:106590. doi: 10.1016/j.vascn.2019.106590. Epub 2019 May 31.

PMID:
31158457
6.

Molecular transport through primary human small intestinal monolayers by culture on a collagen scaffold with a gradient of chemical cross-linking.

Speer JE, Gunasekara DB, Wang Y, Fallon JK, Attayek PJ, Smith PC, Sims CE, Allbritton NL.

J Biol Eng. 2019 Apr 27;13:36. doi: 10.1186/s13036-019-0165-4. eCollection 2019.

7.

Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody.

Émond JP, Labriet A, Desjardins S, Rouleau M, Villeneuve L, Hovington H, Brisson H, Lacombe L, Simonyan D, Caron P, Périgny M, Têtu B, Fallon JK, Klein K, Smith PC, Zanger UM, Guillemette C, Lévesque E.

Drug Metab Dispos. 2019 May;47(5):444-452. doi: 10.1124/dmd.119.086330. Epub 2019 Feb 28.

PMID:
30819787
8.

A Monolayer of Primary Colonic Epithelium Generated on a Scaffold with a Gradient of Stiffness for Drug Transport Studies.

Gunasekara DB, Speer J, Wang Y, Nguyen DL, Reed MI, Smiddy NM, Parker JS, Fallon JK, Smith PC, Sims CE, Magness ST, Allbritton NL.

Anal Chem. 2018 Nov 20;90(22):13331-13340. doi: 10.1021/acs.analchem.8b02845. Epub 2018 Oct 30.

9.

Quantification of membrane transporter proteins in human lung and immortalized cell lines using targeted quantitative proteomic analysis by isotope dilution nanoLC-MS/MS.

Fallon JK, Houvig N, Booth-Genthe CL, Smith PC.

J Pharm Biomed Anal. 2018 May 30;154:150-157. doi: 10.1016/j.jpba.2018.02.044. Epub 2018 Feb 22.

PMID:
29544106
10.

Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles.

Shi P, Liao M, Chuang BC, Griffin R, Shi J, Hyer M, Fallon JK, Smith PC, Li C, Xia CQ.

Xenobiotica. 2018 Nov;48(11):1173-1183. doi: 10.1080/00498254.2017.1397812. Epub 2017 Nov 16.

PMID:
29098941
11.

Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity.

Achour B, Dantonio A, Niosi M, Novak JJ, Fallon JK, Barber J, Smith PC, Rostami-Hodjegan A, Goosen TC.

Drug Metab Dispos. 2017 Oct;45(10):1102-1112. doi: 10.1124/dmd.117.076703. Epub 2017 Aug 2.

PMID:
28768682
12.

Extreme low dose of 5-fluorouracil reverses MDR in cancer by sensitizing cancer associated fibroblasts and down-regulating P-gp.

Ma Y, Wang Y, Xu Z, Wang Y, Fallon JK, Liu F.

PLoS One. 2017 Jun 29;12(6):e0180023. doi: 10.1371/journal.pone.0180023. eCollection 2017.

13.

Multimodal analysis of drug transporter expression in gastrointestinal tissue.

Thompson CG, Fallon JK, Mathews M, Charlins P, Remling-Mulder L, Kovarova M, Adamson L, Srinivas N, Schauer A, Sykes C, Luciw P, Garcia JV, Akkina R, Smith PC, Kashuba ADM.

AIDS. 2017 Jul 31;31(12):1669-1678. doi: 10.1097/QAD.0000000000001554.

14.

Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody.

Fallon JK, Vandeveer AJ, Schlom J, Greiner JW.

Oncotarget. 2017 Mar 28;8(13):20558-20571. doi: 10.18632/oncotarget.16137.

15.

Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS.

Fallon JK, Smith PC, Xia CQ, Kim MS.

Pharm Res. 2016 Sep;33(9):2280-8. doi: 10.1007/s11095-016-1966-5. Epub 2016 Jun 29.

PMID:
27356525
16.

The Effect of Surfactant on Paclitaxel Nanocrystals: An In Vitro and In Vivo Study.

Liu H, Ma Y, Liu D, Fallon JK, Liu F.

J Biomed Nanotechnol. 2016 Jan;12(1):147-53.

PMID:
27301180
17.

UGT concentrations in human rectal tissue after multidose, oral curcumin.

Asher GN, Fallon JK, Smith PC.

Pharmacol Res Perspect. 2016 Feb 23;4(2):e00222. doi: 10.1002/prp2.222. eCollection 2016 Apr.

18.

Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.

Vandeveer AJ, Fallon JK, Tighe R, Sabzevari H, Schlom J, Greiner JW.

Cancer Immunol Res. 2016 May;4(5):452-62. doi: 10.1158/2326-6066.CIR-15-0176. Epub 2016 Feb 26.

19.

Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance.

Knights KM, Spencer SM, Fallon JK, Chau N, Smith PC, Miners JO.

Br J Clin Pharmacol. 2016 Jun;81(6):1153-64. doi: 10.1111/bcp.12889. Epub 2016 Mar 14.

20.

New mouse xenograft model modulated by tumor-associated fibroblasts for human multi-drug resistance in cancer.

Ma Y, Lin Z, Fallon JK, Zhao Q, Liu D, Wang Y, Liu F.

Oncol Rep. 2015 Nov;34(5):2699-705. doi: 10.3892/or.2015.4265. Epub 2015 Sep 9.

21.

Programmed Hydrolysis in Designing Paclitaxel Prodrug for Nanocarrier Assembly.

Fu Q, Wang Y, Ma Y, Zhang D, Fallon JK, Yang X, Liu D, He Z, Liu F.

Sci Rep. 2015 Jul 13;5:12023. doi: 10.1038/srep12023.

22.

Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential.

Margaillan G, Rouleau M, Klein K, Fallon JK, Caron P, Villeneuve L, Smith PC, Zanger UM, Guillemette C.

Drug Metab Dispos. 2015 Sep;43(9):1331-5. doi: 10.1124/dmd.115.065391. Epub 2015 Jun 15.

23.

Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues.

Margaillan G, Rouleau M, Fallon JK, Caron P, Villeneuve L, Turcotte V, Smith PC, Joy MS, Guillemette C.

Drug Metab Dispos. 2015 Apr;43(4):611-9. doi: 10.1124/dmd.114.062877. Epub 2015 Feb 3.

24.

Disulfide bond bridge insertion turns hydrophobic anticancer prodrugs into self-assembled nanomedicines.

Wang Y, Liu D, Zheng Q, Zhao Q, Zhang H, Ma Y, Fallon JK, Fu Q, Haynes MT, Lin G, Zhang R, Wang D, Yang X, Zhao L, He Z, Liu F.

Nano Lett. 2014 Oct 8;14(10):5577-83. doi: 10.1021/nl502044x. Epub 2014 Sep 7.

25.

Theranostic nanoemulsions: codelivery of hydrophobic drug and hydrophilic imaging probe for cancer therapy and imaging.

Yang X, Wang D, Ma Y, Zhao Q, Fallon JK, Liu D, Xu XE, Wang Y, He Z, Liu F.

Nanomedicine (Lond). 2014 Dec;9(18):2773-85. doi: 10.2217/nnm.14.50.

PMID:
25000945
26.

Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancer.

Ma Y, Liu D, Wang D, Wang Y, Fu Q, Fallon JK, Yang X, He Z, Liu F.

Mol Pharm. 2014 Aug 4;11(8):2623-30. doi: 10.1021/mp400778r. Epub 2014 Apr 21.

27.

Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.

Higgins JW, Bao JQ, Ke AB, Manro JR, Fallon JK, Smith PC, Zamek-Gliszczynski MJ.

Drug Metab Dispos. 2014 Jan;42(1):182-92. doi: 10.1124/dmd.113.054783. Epub 2013 Nov 5.

PMID:
24194513
29.

Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring.

Fallon JK, Neubert H, Hyland R, Goosen TC, Smith PC.

J Proteome Res. 2013 Oct 4;12(10):4402-13. doi: 10.1021/pr4004213. Epub 2013 Sep 26.

PMID:
23977844
30.

Characterization of biomolecular nanoconjugates by high-throughput delivery and spectroscopic difference.

Delong RK, Risor A, Kanomata M, Laymon A, Jones B, Zimmerman SD, Williams J, Witkowski C, Warner M, Ruff M, Garrad R, Fallon JK, Hickey AJ, Sedaghat-Herati R.

Nanomedicine (Lond). 2012 Dec;7(12):1851-62. doi: 10.2217/nnm.12.70. Epub 2012 Sep 3.

31.

Effects of direct spiking of silicone oil into a model pMDI formulation.

Fallon JK, Peyron ID, Hickey AJ.

Drug Dev Ind Pharm. 2013 May;39(5):681-6. doi: 10.3109/03639045.2012.687380. Epub 2012 May 26.

PMID:
22630349
32.

Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs.

Garcia-Contreras L, Muttil P, Fallon JK, Kabadi M, Gerety R, Hickey AJ.

Antimicrob Agents Chemother. 2012 May;56(5):2612-8. doi: 10.1128/AAC.06145-11. Epub 2012 Feb 13.

33.

Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry.

Harbourt DE, Fallon JK, Ito S, Baba T, Ritter JK, Glish GL, Smith PC.

Anal Chem. 2012 Jan 3;84(1):98-105. doi: 10.1021/ac201704a. Epub 2011 Dec 5.

34.

In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines.

Heffernan MJ, Zaharoff DA, Fallon JK, Schlom J, Greiner JW.

Biomaterials. 2011 Jan;32(3):926-32. doi: 10.1016/j.biomaterials.2010.09.058. Epub 2010 Oct 20.

35.

Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses.

Muttil P, Pulliam B, Garcia-Contreras L, Fallon JK, Wang C, Hickey AJ, Edwards DA.

AAPS J. 2010 Dec;12(4):699-707. doi: 10.1208/s12248-010-9229-6. Epub 2010 Sep 28.

36.

Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route.

Muttil P, Prego C, Garcia-Contreras L, Pulliam B, Fallon JK, Wang C, Hickey AJ, Edwards D.

AAPS J. 2010 Sep;12(3):330-7. doi: 10.1208/s12248-010-9192-2. Epub 2010 Apr 24.

37.

Absolute quantification of human uridine-diphosphate glucuronosyl transferase (UGT) enzyme isoforms 1A1 and 1A6 by tandem LC-MS.

Fallon JK, Harbourt DE, Maleki SH, Kessler FK, Ritter JK, Smith PC.

Drug Metab Lett. 2008 Aug;2(3):210-22.

PMID:
19356096
38.

Exosomes and HIV Gag bud from endosome-like domains of the T cell plasma membrane.

Booth AM, Fang Y, Fallon JK, Yang JM, Hildreth JE, Gould SJ.

J Cell Biol. 2006 Mar 13;172(6):923-35.

39.

Molecular insights into the pleiotropic effects of plasma on ex vivo-expanded T cells using DNA-microarray analysis.

Ramsborg CG, Windgassen D, Fallon JK, Paredes CJ, Papoutsakis ET.

Exp Hematol. 2004 Oct;32(10):970-90.

PMID:
15504553
40.

Candida albicans in urine can produce testosterone: impact on the testosterone/epitestosterone sports drug test.

Kicman AT, Fallon JK, Cowan DA, Walker C, Easmon S, Mackintosh D.

Clin Chem. 2002 Oct;48(10):1799-801. No abstract available.

41.

Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release.

Fallon JK, Shah D, Kicman AT, Hutt AJ, Henry JA, Cowan DA, Forsling M.

Ann N Y Acad Sci. 2002 Jun;965:399-409.

PMID:
12105115
42.

The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus.

Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT, Hutt AJ.

Br J Pharmacol. 2002 Feb;135(3):649-56.

43.

Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine ("ecstasy"): is metabolism a contributory factor?

Forsling M, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Henry JA.

J Pharm Pharmacol. 2001 Oct;53(10):1357-63.

PMID:
11697543
44.

Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans.

Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, Hutt AJ.

Clin Chem. 1999 Jul;45(7):1058-69. Erratum in: Clin Chem 1999 Sep;45(9):1585.

45.

Low-dose MDMA ("ecstasy") induces vasopressin secretion.

Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M.

Lancet. 1998 Jun 13;351(9118):1784. No abstract available.

PMID:
9635954

Supplemental Content

Loading ...
Support Center